Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors

Triple-negative breast cancer (TNBC) is primarily treated via chemotherapy; in parallel, efforts are made to introduce immunotherapies into TNBC treatment. CD4+ TNFR2+ lymphocytes were reported as Tregs that contribute to tumor progression. However, our published study indicated that TNFR2+ tumor-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Baram, Tamir, Erlichman, Nofar, Dadiani, Maya, Balint-Lahat, Nora, Pavlovski, Anya, Meshel, Tsipi, Morzaev-Sulzbach, Dana, Gal-Yam, Einav Nili, Barshack, Iris, Ben-Baruch, Adit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229590/
https://www.ncbi.nlm.nih.gov/pubmed/34201054
http://dx.doi.org/10.3390/cells10061429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229590/
https://www.ncbi.nlm.nih.gov/pubmed/34201054
http://dx.doi.org/10.3390/cells10061429

Ejemplares similares